Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Coronaviruses have caused several human epidemics and pandemics including the
ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic …
ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic …
[HTML][HTML] Antibody evasion properties of SARS-CoV-2 Omicron sublineages
The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …
Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
K Vanshylla, C Fan, M Wunsch, N Poopalasingam… - Cell host & …, 2022 - cell.com
A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-
CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we …
CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we …
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern
In the absence of virus-targeting small-molecule drugs approved for the treatment and
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA. 1 following homologous and heterologous CoronaVac or BNT162b2 vaccination
The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating
globally. It is important to define reductions in virus neutralizing activity in the serum of …
globally. It is important to define reductions in virus neutralizing activity in the serum of …
Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
S Moriyama, Y Anraku, S Taminishi, Y Adachi… - Nature …, 2023 - nature.com
SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS)
antibodies that exist in diverse individuals as public antibody clones. We rationally selected …
antibodies that exist in diverse individuals as public antibody clones. We rationally selected …
The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA. 1 evolution
The Omicron BA. 1 variant of SARS-CoV-2 escapes convalescent sera and monoclonal
antibodies that are effective against earlier strains of the virus. This immune evasion is …
antibodies that are effective against earlier strains of the virus. This immune evasion is …
[HTML][HTML] Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …
developed as therapeutics and are a major contributor to neutralizing antibody responses …